Meta-analyses evaluating association between CYP2C19 LOF and clinical outcome
| Authors . | No of studies . | No of patients . | LOF vs non-LOF MACE 95% CI . | LOF vs non-LOF stent thrombosis 95% CI . |
|---|---|---|---|---|
| Hulot et al82 | 10 | 11 959 | OR 1.29 (1.12-1.49) | OR 3.45 (2.14-5.57) |
| Mega et al83 | 9 | 9 685 | OR 1.55 (1 LOF) | OR 2.67 (1 LOF) |
| (1.11-2.17) | (1.69-4.22) | |||
| OR 1.76 (2 LOF) | OR 3.97 (2 LOF) | |||
| (1.24-2.50) | (1.75-9.02) | |||
| Bauer et al84 | 15 | 19 328 | OR 1.11 (0.89-1.39) | OR 1.77 (1.31-2.40) |
| Holmes et al29 | 32 | 42 016 | RR 1.18 (1.09-1.28) | RR 1.75 (1.50-2.03) |
| Jin et al85 | 8 | 8 280 | N/R | OR 3.81 (2.27-6.40) |
| Liu et al86 | 18 | 21 441 | OR 1.26 (1.06-1.50) | OR 2.58 (1.77-3.77) |
| Sofi et al87 | 7 | 8 043 | RR 1.96 (1.14-3.37) | RR 3.82 (2.22-6.54) |
| Jang et al88 | 16 | 20 785 | OR 1.42 (1.13-1.78) | OR 2.41 (1.76-3.30) |
| Zabalza et al89 | 13 | 16 360 | HR 1.23 (0.97-1.55) | HR 2.24 (1.5203.30) |
| Mao et al90 | 21 | 23 035 | OR 1.56 (1.21-1.87) | OR 2.08 (1.67-2.60) |
| Yamaguchi et al53 | 7 | 5 307 | N/R | OR 2.65 (1.46-4.84) |
| AHRQ45 | N/R | N/R | RR 1.20 (1.04-1.39) | RR 1.52 (1.17-1.97) |
| Authors . | No of studies . | No of patients . | LOF vs non-LOF MACE 95% CI . | LOF vs non-LOF stent thrombosis 95% CI . |
|---|---|---|---|---|
| Hulot et al82 | 10 | 11 959 | OR 1.29 (1.12-1.49) | OR 3.45 (2.14-5.57) |
| Mega et al83 | 9 | 9 685 | OR 1.55 (1 LOF) | OR 2.67 (1 LOF) |
| (1.11-2.17) | (1.69-4.22) | |||
| OR 1.76 (2 LOF) | OR 3.97 (2 LOF) | |||
| (1.24-2.50) | (1.75-9.02) | |||
| Bauer et al84 | 15 | 19 328 | OR 1.11 (0.89-1.39) | OR 1.77 (1.31-2.40) |
| Holmes et al29 | 32 | 42 016 | RR 1.18 (1.09-1.28) | RR 1.75 (1.50-2.03) |
| Jin et al85 | 8 | 8 280 | N/R | OR 3.81 (2.27-6.40) |
| Liu et al86 | 18 | 21 441 | OR 1.26 (1.06-1.50) | OR 2.58 (1.77-3.77) |
| Sofi et al87 | 7 | 8 043 | RR 1.96 (1.14-3.37) | RR 3.82 (2.22-6.54) |
| Jang et al88 | 16 | 20 785 | OR 1.42 (1.13-1.78) | OR 2.41 (1.76-3.30) |
| Zabalza et al89 | 13 | 16 360 | HR 1.23 (0.97-1.55) | HR 2.24 (1.5203.30) |
| Mao et al90 | 21 | 23 035 | OR 1.56 (1.21-1.87) | OR 2.08 (1.67-2.60) |
| Yamaguchi et al53 | 7 | 5 307 | N/R | OR 2.65 (1.46-4.84) |
| AHRQ45 | N/R | N/R | RR 1.20 (1.04-1.39) | RR 1.52 (1.17-1.97) |
AHRQ, Agency for Healthcare Research and Quality; N/R, not reported.